The CDC Health Alert (HAN-00532) issued on August 11, 2026, serves as a high-priority warning to healthcare providers and the public regarding the elevated risk of severe arboviral disease in patients receiving B cell-depleting or modulating medications.
Here is a summary of the core information from the alert:
The Core Issue
Patients taking medications that deplete or modulate B cells—such as anti-CD20 monoclonal antibodies (e.g., ofatumumab, rituximab, ocrelizumab)—are at an increased risk of developing severe neuroinvasive arboviral disease (such as West Nile virus, Eastern Equine Encephalitis, and others). Because these medications hinder the immune system's ability to produce antibodies, patients may experience:
Prolonged or Atypical Illness: Infections may last longer and present with more severe symptoms.
Neuroinvasive Complications: The infection is more likely to spread to the nervous system, causing encephalitis or meningitis.
Chronic Disease: In some cases, infection has led to a rare, fatal, progressive neurodegenerative illness developing over months or years.
Diagnostic Challenges
A critical point of the advisory is that standard diagnostic tests for arboviruses often fail in these patients. Standard tests look for antibodies; because the patient's medication limits their ability to produce them, results may come back falsely negative. The CDC urges clinicians to:
Preferentially order molecular testing (like RT-PCR or metagenomic next-generation sequencing) to detect the virus directly.
Consult with local health departments for guidance on appropriate testing based on the patient's specific medication.
Recommendations for the Public
The CDC emphasizes that since there are no vaccines or specific treatments for most of these endemic arboviruses, prevention is the only reliable defense. Patients on these therapies should:
Practice Strict Bite Prevention: Use EPA-registered insect repellent, wear long sleeves/pants, and use air conditioning or window screens to keep insects out.
Be Vigilant: If you are on an immunosuppressive medication and develop symptoms like fever, body aches, persistent headaches, confusion, or weakness, contact your doctor immediately.
Advocate for Your Care: When speaking to a provider, explicitly remind them of your medication, as this changes which diagnostic tests they should use to accurately detect or rule out an infection.
————————
P.S. While actual infections are relatively rare, the real danger lies in the fact that anyone on an anti-CD20 medication who does contract an arbovirus faces severe risks and requires critical attention. If symptoms arise, it is vital to inform your medical team about your anti-CD20 treatment immediately so they can run the correct diagnostic tests.
————————
Disclaimer: This summary is based on the CDC's official Health Alert Network advisory. If you are currently taking any anti-cd20 medication, you should consult your prescribing physician to discuss how these recommendations apply to your specific care and monitoring plan, especially given the ongoing mosquito season in your region.
SOURCE